Immunology and Allergology >>>> Vaccination against meningococcal infection
Vaccination against meningococcal infection.
On the recommendation of WHO, vaccination against meningococcal infection is carried out in risk groups and during periods of mass epidemics for personal protection and to prevent bacterial carriage. For vaccination, polysaccharide vaccine A, polysaccharide vaccine A + C (Meningo), polysaccharide vaccine A + C + Y + W135 (Mentsevax) are used.
Children of school age and adults who are at risk (travel to an endemic zone, an epidemic in the region) are subject to vaccination. In schoolchildren and adults, a single dose of the vaccine induces immunity for a period of 3 years. In children under four years of age, antibody activity after vaccination gradually decreases over a period of 2 years. In infants 3 months of age, the vaccine does not produce protective antibodies (no reliable evidence). In infancy, vaccination is carried out only according to indications.
Vaccination is safe, there are symptoms of redness of the injection site, rarely an increase in temperature to 38 degrees.
Contraindications to vaccination are any diseases in the acute form of the course, progressive diseases, general impairment of well-being, allergies to components, pregnancy and breastfeeding (the effect has not been studied), Guillain-Barré syndrome (warn the doctor).
Read
Read
